Alvotech offers asymmetric biosimilar upside after FDA inspection relief, but its $1.31 billion debt load makes Q4 2026 approvals and commercial execution critical.
Overview
Alvotech is a specialized, pure-play biosimilar company developing and manufacturing complex biologics at its Reykjavik, Iceland facility, then commercializing them through partners rather than maintaining a redundant global sales infrastructure. Its portfolio targets blockbuster franchises in immunology, bone health, oncology, and ophthalmology, with more than $35 billion of U.S. addressable market. AVT02 is approved in 55+ countries and AVT04 is launched across the U.S., Europe, Japan, and Canada; AVT03, AVT05, and AVT06 are positioned for U.S. FDA decisions in Q4 2026. **The key positive change is the FDA’s July 2026 VAI classification**, which closed the plant inspection and reduced the regulatory overhang that had delayed U.S. launches. Financially, H1 2026 was weak: adjusted revenue fell 30.8% to $211.9 million, adjusted EBITDA declined to $46.9 million, and IFRS results swung to a $65.8 million loss. Management nevertheless reaffirmed 2026 revenue guidance of $650–$700 million and adjusted EBITDA of $180–$220 million. **Valuation is highly asymmetric but debt-dependent**: at $3.95, the report calculates a probability-weighted 5-year value of $10.87, while $1.31 billion of debt and $72.2 million of H1 cash interest create meaningful dilution and solvency risk.